People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsingremitting or active secondary progressive disease) taking cladribine tablets.

Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L.h., Oreja-Guevara, C., Selchen, D., et al. (2022). Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary [10.2217/nmt-2022-0027].

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

Centonze, Diego;
2022-10-24

Abstract

People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsingremitting or active secondary progressive disease) taking cladribine tablets.
24-ott-2022
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
COVID-19
cladribine tablets
clinical research
lay summary
multiple sclerosis
plain language summary
vaccination
Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L.h., Oreja-Guevara, C., Selchen, D., et al. (2022). Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary [10.2217/nmt-2022-0027].
Rieckmann, P; Centonze, D; Giovannoni, G; Hua, Lh; Oreja-Guevara, C; Selchen, D; Sørensen, Ps; Vermersch, P; Wiendl, H; Salloukh, H; Yamout, B
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/309644
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact